Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 16Rectal Neoplasms 4Colonic Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Neoplasms 2Biliary Tract Neoplasms 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastric Cancer Adenocarcinoma Metastatic 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Dihydropyrimidine Dehydrogenase Deficiency 1Desmoid Tumors 1Craniopharyngioma 1Colorectal Cancer Metastatic 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Teclison Ltd.

Phase 2 Recruiting
110 enrolled
GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡